Prothena Corp. Plc PRTA 深 沪
已收盘 02-06 16:00:00 美东时间
8.91
+0.560
+6.71%
华盛通- 最 高8.99
- 今 开8.58
- 成交量 58.10万股
- 最 低 8.56
- 昨 收 8.35
- 总市值 4.80亿
- 52周最高 16.665
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 4.32
- 委 比 -14.29%
- 总股本 5383.00万
- 历史最高 79.749
- 量 比 1.32
- 振 幅 5.15%
- 历史最低 4.32
- 每 手 1
- 风险率 2.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prothena Board Member Paula Cobb Resigns
Prothena ( ($PRTA) ) has provided an update. On December 10, 2025, Paula Cobb a...
2025-12-13 05:48
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19
Citizens analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $11 to $19.
2025-12-01 21:17
Prothena Shareholders Approve Capital Reduction Proposal
Prothena ( ($PRTA) ) has provided an announcement. On November 19, 2025, Prothe...
2025-11-20 06:06
Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a scientific presentation at
2025-11-20 05:09
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.
2025-11-12 22:24
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $11
RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $10 to $11.
2025-11-08 03:21
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
2025-10-29 09:25
